These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26678610)

  • 1. Transcriptional kinases: Less is more (or less).
    Boyer TG
    Nat Chem Biol; 2016 Jan; 12(1):4-5. PubMed ID: 26678610
    [No Abstract]   [Full Text] [Related]  

  • 2. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
    Dale T; Clarke PA; Esdar C; Waalboer D; Adeniji-Popoola O; Ortiz-Ruiz MJ; Mallinger A; Samant RS; Czodrowski P; Musil D; Schwarz D; Schneider K; Stubbs M; Ewan K; Fraser E; TePoele R; Court W; Box G; Valenti M; de Haven Brandon A; Gowan S; Rohdich F; Raynaud F; Schneider R; Poeschke O; Blaukat A; Workman P; Schiemann K; Eccles SA; Wienke D; Blagg J
    Nat Chem Biol; 2015 Dec; 11(12):973-980. PubMed ID: 26502155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11.
    Cee VJ; Chen DY; Lee MR; Nicolaou KC
    Angew Chem Int Ed Engl; 2009; 48(47):8952-7. PubMed ID: 19844931
    [No Abstract]   [Full Text] [Related]  

  • 4. Binding patterns and structure-activity relationship of CDK8 inhibitors.
    Ma D; Chen X; Shen XB; Sheng LQ; Liu XH
    Bioorg Chem; 2020 Mar; 96():103624. PubMed ID: 32078847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
    Philip S; Kumarasiri M; Teo T; Yu M; Wang S
    J Med Chem; 2018 Jun; 61(12):5073-5092. PubMed ID: 29266937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Novel and Potent Cyclin-Dependent Kinase 8/19 (CDK8/19) Inhibitor for the Treatment of Cancer.
    Xu J; Qi H; Wang Z; Wang L; Steurer B; Cai X; Liu J; Aliper A; Zhang M; Ren F; Zhavoronkov A; Ding X
    J Med Chem; 2024 May; 67(10):8161-8171. PubMed ID: 38690856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential.
    Fujimoto J; Hirayama T; Hirata Y; Hikichi Y; Murai S; Hasegawa M; Hasegawa Y; Yonemori K; Hata A; Aoyama K; Cary DR
    Bioorg Med Chem; 2017 Jun; 25(12):3018-3033. PubMed ID: 28392276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV Transcription Is Independent of Mediator Kinases.
    Cary DC; Rheinberger M; Rojc A; Peterlin BM
    AIDS Res Hum Retroviruses; 2019 Aug; 35(8):710-717. PubMed ID: 31044597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase 7 inhibitors in cancer therapy.
    Wang M; Wang T; Zhang X; Wu X; Jiang S
    Future Med Chem; 2020 May; 12(9):813-833. PubMed ID: 32208930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
    Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
    Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iterative conversion of cyclin binding groove peptides into druglike CDK inhibitors with antitumor activity.
    Premnath PN; Craig SN; Liu S; Anderson EL; Grigoroudis AI; Kontopidis G; Perkins TL; Wyatt MD; Pittman DL; McInnes C
    J Med Chem; 2015 Jan; 58(1):433-42. PubMed ID: 25454794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances on CDK inhibitors: An insight by means of in silico methods.
    Tutone M; Almerico AM
    Eur J Med Chem; 2017 Dec; 142():300-315. PubMed ID: 28802482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Search of Novel CDK8 Inhibitors by Virtual Screening.
    Kumarasiri M; Teo T; Yu M; Philip S; Basnet SK; Albrecht H; Sykes MJ; Wang P; Wang S
    J Chem Inf Model; 2017 Mar; 57(3):413-416. PubMed ID: 28191946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Targeting of the General RNA Polymerase II Transcription Machinery.
    Martin RD; Hébert TE; Tanny JC
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palbociclib (Ibrance) for metastatic breast cancer.
    Med Lett Drugs Ther; 2015 Aug; 57(1475):115-6. PubMed ID: 26262882
    [No Abstract]   [Full Text] [Related]  

  • 17. Synthesis and biological evaluation of tetrahydro[1,4]diazepino[1,2-a]indol-1-ones as cyclin-dependent kinase inhibitors.
    Putey A; Fournet G; Lozach O; Perrin L; Meijer L; Joseph B
    Eur J Med Chem; 2014 Aug; 83():617-29. PubMed ID: 24998602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
    Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
    Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of 1,7-annulated indoles and their applications in the studies of cyclin dependent kinase inhibitors.
    Zhu G; Conner SE; Zhou X; Chan HK; Shih C; Engler TA; Al-Awar RS; Brooks HB; Watkins SA; Spencer CD; Schultz RM; Dempsey JA; Considine EL; Patel BR; Ogg CA; Vasudevan V; Lytle ML
    Bioorg Med Chem Lett; 2004 Jun; 14(12):3057-61. PubMed ID: 15149644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.